Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus

TC-6987 is a selective nicotinic α-7 receptor ligand (open channel stabilizer) that has demonstrated potent anti-inflammatory/antioxidant properties in animal models. Following the oral administration of a 1mg/kg dose of TC-6987 to diabetic mice (db/db mouse) for 7 weeks, numerous metabolic improvements were observed. Specifically, plasma glucose and triglyceride concentrations declined by approximately 30%; Hb1Ac was reduced by nearly 50%; and TNF-α declined more than 60% relative to control db/db mice Therefore, it appears that TC-6987 could prove beneficial in reducing elevated glucose concentrations in diabetic patients as well as in ameliorating organ damage associated with inflammation, oxidative stress and hyperglycemia.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: TC-6987; Drug: Placebo

Detailed Description

This is a Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, and pharmacokinetic parameters of TC-6987 in subjects with type 2 diabetes mellitus (T2DM). The study is organized into three phases: (a) Screening phase consisting of a 1-week Screening (Week -5)and a 4-week Washout (Week -4 to Day 1); (b) 4-week, Double-Blind Treatment (Day 1 to Week 4) during which subjects are randomized to either TC-6987 (20 mg on Day 1 and 10 mg from Day 2 to Week 4) or placebo; and (c) 2-week Follow-Up (Week 6). Unscheduled visits will be allowed between visits from Washout through Follow-up to evaluate a subject's glycemic status or other safety issues, as required. Subjects will fast overnight for a minimum of 10 hrs and refrain from drinking alcohol 24 hrs prior to each visit.

• Study Type: Interventional
• Enrollment (Actual): 440
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Jonesboro, Arkansas, United States, 72401
      • Clopton Clinic
    • Mountain Home, Arkansas, United States, 72653
      • NCA Medical Center
  • California
    • Buena Park, California, United States, 90620
      • Associated Pharmaceutical Research Center
  • Illinois
    • Chicago, Illinois, United States, 60607
      • Cedar Crosse Research Center
  • Missouri
    • St. Louis, Missouri, United States, 63117
      • Medex Healthcare Research, Inc
  • Nevada
    • Henderson, Nevada, United States, 89052
      • Om Medical
  • New York
    • New York, New York, United States, 10004
      • Medex Healthcare Research, Inc
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27103
      • PMG Research of WS
  • Ohio
    • Cleveland, Ohio, United States, 44122
      • Rapid Medical Research, Inc.
    • Dayton, Ohio, United States, 45439
      • Providence Health Partners - Center for Research
  • Rhode Island
    • Warwick, Rhode Island, United States, 02888
      • Omega Medical Research
  • South Carolina
    • Columbia, South Carolina, United States, 29201
      • Ellipsis Research
    • Mt. Pleasant, South Carolina, United States, 29464
      • PMG Research of Charleston
  • Tennessee
    • Knoxville, Tennessee, United States, 37923
      • New Phase Research And Development
  • Texas
    • Houston, Texas, United States, 77093
      • Mercury Clinical Research
    • San Antonio, Texas, United States, 78209
      • Quality Research, Inc.
  • Utah
    • Salt Lake City, Utah, United States, 84124
      • Highland Clinical Research
  • Virginia
    • Norfolk, Virginia, United States, 23510
      • Strelitz Diabetes Center, Eastern Virginia Medical School

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or postmenopausal/surgically sterile females
• Being treated for T2DM with oral antidiabetic agents (excluding glitazones)
• BMI limit ≤ 38
• Subjects at least 80% compliant on reporting daily SMBG values during washout
• At the end of washout the subject's fasting SMBG is higher than it was at the start of washout and the fasting SMBG ≤ 280.g treated for T2DM with oral antidiabetic agents (excluding glitazones)

Exclusion Criteria:

• Type 1 diabetes mellitus
• Severe complications of T2DM (especially diabetic retinopathy imminently requiring treatment for preserving or restoring vision, diabetic neuropathy with symptomatic orthostatic hypotension, urinary retention, gastric stasis, or pedal ulcers)
• Current treatment with insulin or a glitazone
• Use of moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitors
• FSH level of < 35 IU/L and a LH level < 25 IU/L except for confirmed surgically sterile women with functioning ovaries
• Significant cardiovascular diseases (including arrhythmia) or congestive heart failure, or severe ischemic disease within the last 3 months prior to Screening, or evidence of stroke, myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty
• History of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, CV, GI, or urological disorder; or diagnosis of major depressive disorder; if stable medical disorder, any medical treatment must be stable for last 2 months prior to Screening
• History of diabetic ketoacidosis
• Patients who have an increased red blood cell (RBC) turn-over or thalassemia or anemia
• Known HIV or history of viral hepatitis type B or C
• Systemic infection with TB
• Current or previous use of oral or injectable corticosteroids 3 months prior to screening.
• Subject has persistent, uncontrolled severe hypertension as indicated by a systolic blood pressure > 180 mmHg or a diastolic blood pressure of > 110 mmHg, with or without treatment
• Subject has had a malignancy in the last 5 years, except for successfully treated basal or squamous cell carcinoma of the skin or of the cervix
• Subject is receiving chemotherapy
• Tobacco user within 4 months prior to Screening
• Smoking cessation therapy within 4 months prior to Screening and/or planned during the study
• Use of prohibited concomitant medications including psychoactive agents
• History within 6 months prior to Screening of alcohol abuse or illicit drug abuse
• Was administered study medication in another clinical trial in the past 3 months prior to Screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo	Drug: Placebo; Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
EXPERIMENTAL: TC-6987	Drug: TC-6987; TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in fasting plasma glucose (FPG)	The primary efficacy endpoint will be FPG values obtained at Week 4 compared to Day 1 (baseline). This change from baseline will be analyzed using MMRM techniques with an alpha of 0.10 (one-sided), to examine differences between the TC-6987 and placebo treatment cohorts. This change from baseline will be analyzed using the primary efficacy endpoints for the mITT analysis set. The efficacy analyses based on the Per Protocol (PP) analysis set will be considered secondary.	Day 1 and Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in FPG from Day 1 (Baseline) at each time point	Change in FPG from Day 1 (Baseline) compared to weeks 1 and 4	Day 1, Week 1 and Week 4
Change in FPG and insulin from Day 1 (Baseline) at each time point	Change in FPG and insulin from Day 1 (Baseline) compared to weeks 1 and 4	Day 1, Week 1 and Week 4
Change in AUC FPG from Day 1 (Baseline) and at Week 4	Change in AUC FPG from Day 1 (Baseline) compared to weeks 1 and 4	Day 1 and Week 4
Change in AUC insulin from Day 1 (Baseline) at Week 4	Change in AUC insulin from Day 1 (Baseline) compared to week 4	Day 1 and Week 4

Collaborators and Investigators

• Sponsor: Targacept Inc.
• Investigators: Principal Investigator: Aaron Vinik, MD, Strelitz Diabetes Center, Eastern Virginia Medical School

Study record dates

Study Major Dates

• Study Start: January 1, 2011
• Primary Completion (ACTUAL): January 1, 2012
• Study Completion (ACTUAL): January 1, 2012

Study Registration Dates

• First Submitted: February 9, 2011
• First Submitted That Met QC Criteria: February 9, 2011
• First Posted (ESTIMATE): February 10, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): September 13, 2013
• Last Update Submitted That Met QC Criteria: September 3, 2013
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Keywords: Type 2 Diabetes; Type 2 Diabetes Mellitus
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: TC-6987-23-CRD-002